Form 4: Denali Therapeutics' Chief Medical Officer Carole Ho Sells Shares to Cover Tax Obligations and Under 10b5-1 Plan

Chief Medical Officer of Denali Therapeutics, Carole Ho, sold shares of DNLI stock on August 20 and 21, 2024, to cover tax obligations and under a pre-arranged 10b5-1 trading plan.

Summary

• Carole Ho, Chief Medical Officer of Denali Therapeutics Inc. (DNLI), reported the sale of company stock on August 20 and 21, 2024.
• On August 20, 2024, 2,453 shares of common stock were sold at a weighted average price of $23.79 per share.
• On August 21, 2024, two transactions occurred: 14,098 shares were sold at a weighted average price of $24.41 per share, and 5,907 shares were sold at a weighted average price of $24.96 per share.
• The sales were executed to satisfy tax obligations related to the settlement of previously vested restricted stock units and pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2023.
• Following these transactions, Carole Ho directly owns 118,810 shares of common stock, including unvested RSUs, and indirectly owns 183,219 shares through the Rohatgi-Ho Family 2009 Revocable Trust and 25,000 shares through The Rohatgi-Ho Irrevocable GST Trust.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating routine stock sales by an insider. The sales are partly to cover tax obligations and under a pre-arranged plan, suggesting no particular cause for alarm or excitement.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating they were planned in advance and not based on current insider information.

Industry Context

Insider sales are a common occurrence in publicly traded companies. It is important to consider the context of these sales, such as whether they are part of a pre-planned trading strategy or related to personal financial needs.

Comparison to Industry Standards

• It's common for executives at publicly traded biotech companies like Denali Therapeutics to have a significant portion of their compensation in stock and options.
• Sales to cover tax obligations related to vesting RSUs are a standard practice.
• The use of 10b5-1 trading plans is a common method for insiders to sell shares without raising concerns about insider trading, similar to practices at companies like Biogen or Amgen.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholder sentiment, but the pre-planned nature of the sales mitigates this concern.

Key Dates